Amicus Therapeutics, Inc.
$14.46
0%
2026-04-21 06:54:02
amicusrx.com
NGM: FOLD
Explore Amicus Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.54 B
Current Price
$14.46
52W High / Low
$14.48 / $5.51
Stock P/E
—
Book Value
$0.88
Dividend Yield
—
ROCE
4.84%
ROE
-11.58%
Face Value
—
EPS
$-0.09
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
511
Beta
0.48
Debt / Equity
161.3
Current Ratio
2.84
Quick Ratio
1.88
Forward P/E
17.66
Price / Sales
7.16
Enterprise Value
$4.69 B
EV / EBITDA
111.78
EV / Revenue
7.39
Rating
Hold
Target Price
$14.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 2. | Jazz Pharmaceuticals plc | $200.82 | — | $12.38 B | — | 5.5% | -8.47% | $207.48 / $97.5 | $70.3 |
| 3. | Veradermics, Incorporated | $73.97 | — | $2.85 B | — | -49.88% | -72.06% | $80.9 / $32 | $-131.48 |
| 4. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
| 5. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 6. | Marker Therapeutics, Inc. | $1.67 | — | $27.84 M | — | -74.05% | -68.81% | $4.07 / $0.81 | $1.01 |
| 7. | NervGen Pharma Corp. | $4 | — | $464.51 M | — | -721.31% | -14.58% | $8.49 / $2.57 | $-0.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 185.21 M | 169.06 M | 154.69 M | 125.25 M | 149.71 M | — |
| Operating Profit | 15.95 M | 34.27 M | -7.77 M | -7.95 M | 15.97 M | — |
| Net Profit | 1.69 M | 17.31 M | -24.42 M | -21.69 M | 14.74 M | — |
| EPS in Rs | 0.01 | 0.06 | -0.08 | -0.07 | 0.05 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 634.21 M | 528.29 M | 399.36 M | 329.23 M |
| Operating Profit | 34.49 M | 34.06 M | -73.49 M | -204.43 M |
| Net Profit | -27.11 M | -56.11 M | -151.58 M | -236.57 M |
| EPS in Rs | -0.09 | -0.18 | -0.48 | -0.75 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 949.87 M | 785.03 M | 777.88 M | 724.17 M |
| Total Liabilities | 675.63 M | 590.99 M | 617.71 M | 601.12 M |
| Equity | 274.24 M | 194.04 M | 160.17 M | 123.05 M |
| Current Assets | 676.17 M | 504.74 M | 483.06 M | 423.82 M |
| Current Liabilities | 237.83 M | 148.7 M | 167.69 M | 139.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 33.15 M | -33.89 M | -69.09 M | -166.57 M |
| Investing CF | -46.43 M | -0.56 M | 98.06 M | 92.32 M |
| Financing CF | 0.61 M | 5.12 M | 61.68 M | -7.46 M |
| Free CF | 29.85 M | -37.44 M | -76.53 M | -170.34 M |
| Capex | -3.3 M | -3.55 M | -7.44 M | -3.77 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 32.29% | 21.3% | — | — |
| Earnings Growth % | 62.99% | 35.92% | — | — |
| Profit Margin % | -10.62% | -37.96% | -71.85% | — |
| Operating Margin % | 6.45% | -18.4% | -62.09% | — |
| Gross Margin % | 89.98% | 90.65% | 88.28% | — |
| EBITDA Margin % | 5.56% | -23.06% | -60.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.